MARKET

CNSP

CNSP

CNS PHARMACEUTICALS, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.800
+0.170
+6.46%
Closed 19:41 03/01 EST
OPEN
2.770
PREV CLOSE
2.630
HIGH
2.830
LOW
2.700
VOLUME
266.40K
TURNOVER
--
52 WEEK HIGH
5.62
52 WEEK LOW
1.258
MARKET CAP
70.84M
P/E (TTM)
-4.9304
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
BRIEF-CNS Pharmaceuticals Berubicin Trial Is On Schedule To Commence In March 2021
reuters.com · 4d ago
CNS gives timeline update for Berubicin trial
CNS Pharmaceuticals (CNSP) indicated that the clinical program for Berubicin is on track to start enrolling patients in March 2021.CNS' lead product candidate, Berubicin, is a novel anthracycline and the first
Seekingalpha · 4d ago
CNS Pharmaceuticals Berubicin Trial is On Schedule to Commence in March 2021
, /PRNewswire/ -- (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today indicated that the clinical progra...
PR Newswire - PRF · 4d ago
Thinking about buying stock in Sundial Growers, electroCore, Arlo Technologies, Salarius Pharmaceuticals, or CNS Pharmaceuticals?
NEW YORK, Feb. 24, 2021 /PRNewswire via COMTEX/ -- NEW YORK, Feb. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL,...
PR Newswire - PRF · 5d ago
WPD Pharmaceuticals inks IMP deal with CNS Pharmaceuticals
WPD Pharmaceuticals (WPDPF) has signed an agreement with CNS Pharmaceuticals (CNSP) to obtain Investigational Medicinal Product ((IMP)) for use in the planned clinical trials of Berubicin.Berubicin is a novel anthracycline candidate for
Seekingalpha · 5d ago
WPD Pharmaceuticals Announces Berubicin Supply Agreement With CNS Pharmaceuticals
VANCOUVER, British Columbia, Feb. 24, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals (CSE:WBIO) (8SV1.F) ("WPD" or the "Company") today announced that it has signed an agreement with CNS
Benzinga · 5d ago
WPD Pharmaceuticals Announces Berubicin Supply Agreement for the Upcoming Clinical Trials
VANCOUVER, British Columbia, Feb. 24, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals (CSE:WBIO) (8SV1.F) ("WPD" or the “Company”) today announced that it has signed an agreement with CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS”) to obtain Investigational M...
GlobeNewswire · 5d ago
Polish Regulatory Authority Issues Positive Opinion For CNS Pharma's Brain Cancer Candidate
Benzinga · 02/18 18:45
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CNSP. Analyze the recent business situations of CNS PHARMACEUTICALS, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CNSP stock price target is 8.33 with a high estimate of 10.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 19
Institutional Holdings: 1.11M
% Owned: 4.39%
Shares Outstanding: 25.30M
TypeInstitutionsShares
Increased
0
0
New
6
1.01M
Decreased
1
256
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About CNSP
CNS Pharmaceuticals Inc. is a preclinical stage pharmaceutical company. The Company is focused on developing anticancer drug candidates for the treatment of brain and central nervous system tumors. The Company is focused on developing its lead drug candidate, Berubicin for the treatment of glioblastoma. Glioblastoma are tumors that arise from astrocytes, which are star-shaped cells making up the supportive tissue of the brain. Berubicin is an anthracycline, a class of drugs that are among the chemotherapy drugs, which intercalates into Deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity. It results in the inhibition of DNA replication and repair, and Ribonucleic acid (RNA) and protein synthesis.

Webull offers kinds of CNS Pharmaceuticals Inc stock information, including NASDAQ:CNSP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNSP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CNSP stock methods without spending real money on the virtual paper trading platform.